Daily · Post Line
An estimated 2.1 million new cancer cases will be diagnosed in the United States this year, with 626,000 deaths expected. However, personalized mRNA cancer vaccines—developed using the same mRNA technology as COVID-19 vaccines—are showing promising results against certain cancers, despite conflicting signals from U.S. officials regarding mRNA’s safety and potential. Companies like Moderna and Merck are leading this effort by combining mRNA vaccines with immunotherapy drugs.
Late-stage studies demonstrate that these vaccines train the immune system to target tumor-specific mutations, offering hope for patients with melanoma, lung, breast, pancreatic, prostate, and other cancers. One study has shown melanoma can be kept at bay for five years. The vaccines work by helping the immune system recognize tumor-specific markers, allowing it to attack cancer cells while sparing healthy tissue.
Researchers have conducted over 120 clinical trials since the early 2000s, with notable successes in melanoma, pancreatic, and brain cancers. Trials show reduced recurrence and spread in melanoma patients treated with vaccines and immunotherapy. Scientists are also exploring combinations with checkpoint inhibitor therapies to enhance immune responses.
Despite progress, challenges remain, such as the lengthy development timeline (10–15 years) and ongoing research to improve tumor target identification. Sources include Mass General Brigham Cancer Institute, Reuters, The New England Journal of Medicine, National Institutes of Health, National Cancer Institute, and the American Cancer Society.
Source: USA Today
